5.2.2. analgesics. use simple analgesics fails provide adequate benefit, consider using neuropathic agents, improvement, consider involving specialist pain management centre interest pelvic pain. chronic pelvic pain well defined involves multiple mechanisms described previous sections. management requires holistic approach biological, psychological social components. studies specifically looked medications used cppps , therefore, wider look literature undertaken specific research required. agents concerned divided ease description. combinations often provide greater benefit individual agents . may also allow lower individual dosages thus minimise side-effects. aim using drugs allow patients improve qol. best measured assessing function well pain severity. use agents allow this, withdrawn. unfortunately, failure one agent exclude potential benefit alternative. benefit limited side-effects, lowest effective dose found (by dose titration). sometimes, patients prefer higher level pain fewer side effects. 5.2.2.1. mechanisms action mechanisms action discussed appropriate drug headings below. 5.2.2.2. comparisons within groups terms efficacy safety paracetamol (acetaminophen) paracetamol well-tolerated analgesic class own. antipyretic analgesic central mechanism action . often available counter without prescription. review questions routine use first-line analgesic based inadequate evidence efficacy many pain conditions including dysmenorrhoea . effective patients individual responses reviewed deciding longer term use. non-steroidal anti-inflammatory agents agents anti-inflammatory, antipyretic analgesics act inhibiting enzyme cyclooxygenase (cox). peripheral effect, hence use conditions involving peripheral inflammatory mechanisms. commonly used pelvic pain; many available counter usually well-tolerated. insufficient evidence suggest one nsaid another pelvic pain. guidelines use nsaids cox-2 selective agents developed. side-effects paracetamol, including indigestion, headaches drowsiness. evidence benefit chronic pelvic pain weak non-existent often limited side-effects. pelvic pain inflammatory processes considered important, dysmenorrhoea , nsaids effective placebo paracetamol, higher incidence side-effects. pelvic pain central mechanisms may incriminated, endometriosis evidence lacking nsaids despite common use. practical level, nsaids considered use, tried (having regard cautions contraindications) patient reviewed improvement function well analgesia. achieved, side-effects limiting, withdrawn. neuromodulators agents simple analgesics used modulate neuropathic centrally mediated pain. several classes commonly used recognised benefits pain medicine. taken regular basis side-effects may limit use potential dependence-forming. uk, nice reviewed pharmacological management neuropathic pain . evidence treatment cppps lacking present painful conditions. chapter, evidence non-pelvic pain sources. general method using agents titrating dose benefit side-effects. aim patients improvement qol, often best assessed alterations function. common use agents combination studies comparing different agents other, combination, lacking. agents also used specific conditions. early identification neuropathic pain simple questionnaire could facilitate targeted therapy neuromodulators . antidepressantstricyclic antidepressants tricyclic antidepressants (tcas) multiple mechanisms action frequently limited side-effects. tricyclic antidepressants long history use pain medicine subjected cochrane review , suggesting effective neuropathic pain. amitriptyline commonly used doses 10-75 mg/day (sometimes rising 150 mg/day). titrated benefit side-effects taken night . nortriptyline imipramine used alternatives. antidepressants duloxetine snri antidepressant licensed use depression, sui neuropathic pain. evidence benefit diabetic neuropathy fibromyalgia dose 60 mg/day . side-effects common may result discontinuation. anticonvulsants anticonvulsants commonly used management neuropathic pain. general studies looking particularly pelvic pain. individual agents systematically reviewed. use suggested nice neuropathic pain guidelines . carbamazepine long history use neuropathic pain. evidence exists benefit . trials trend short duration, showing moderate benefit. side-effects; may serious. longer first choice agent. anticonvulsant agents available fewer serious side-effects. gabapentinoidsthere growing awareness evidence risk dependence misuse gabapentinoids . formal assessment efficacy benefit side-effects (both pain qol) required patient order determine lowest effective dose longer-term treatment used. gabapentin commonly used neuropathic pain systematically reviewed . demonstrates good evidence postherpetic neuralgia diabetic neuropathy evidence neuropathies limited. double-blind rct looking cppps women obvious pathology demonstrated benefits higher levels side effect . pregabalin commonly used neuromodulator good evidence efficacy neuropathic conditions . dose benefit range 300-600 mg/day. evidence central neuropathic pains inadequate. patients gain moderate significant benefit gain benefit drug discontinued. agents used management neuropathic pain best administered specialists management pain familiar use. tend considered standard options exhausted. good pain management, used part comprehensive multi-dimensional management plan. opioids recent years opioids used extensively managing chronic non-cancer pain. increasing evidence role limited population, may beneficial small number patients low dose managed setting . clear evidence harm significant professional, public political interest. use beneficial acute pain cancer pain management particularly towards end life. often patients stop taking oral opioids due side effects insufficient analgesic effect . clear evidence harm including effects endocrine immune systems well growing understanding opioid-induced hyperalgesia . limited guidance best method tapering dose opioids aim stopping finding lowest effective dose . opioids used conjunction management plan consultation clinicians experienced use. suggested pain management unit involved along patient primary care physician. ensure arrangements formal monitoring, follow-up review. opioids used pain remains, working stopped even alternative . risk harm increases substantially doses 120 mg/day morphine equivalence guidance suggests regular (at least annual) review patients 50 mg/day morphine equivalence pain specialist involvement 90 mg/day morphine equivalence . well-established guidelines use opioids pain management well considering potential risks . opioid reduction optimisation undertaken opioids providing clear measurable benefit. also information available online patients . opioids aware web-based resource patients healthcare professionals, jointly produced faculty pain medicine royal college anaesthetists public health england, support prescribing opioid medicines pain. https://fpm.ac.uk/opioids-aware. cannabinoids increasing interest changes national regulations regarding use cannabinoids medicinal use. regarding pain evidence base use cannabinoids weak [448-450] well conducted clinical trials necessary. area guidance research likely coming years.